In April 2026, researchers at Scripps Research and the Karolinska Institute published a study in Nature describing an experimental HIV vaccine that produced broadly protective antibodies in every rhesus macaque tested. It is the first time vaccination alone has produced this outcome with this level of consistency.
Follow-up work published in Nature in June and August 2026 expanded on the findings, showing that the immune response remained strong for months and appeared to mature over time.
Why this is different
HIV has been one of the hardest vaccine targets in medical history. Three things make it difficult:
- It mutates fast. The virus makes errors when it copies itself, so it evolves to escape immune responses.
- It hides. HIV integrates into the DNA of the cells it infects, making it invisible to antibodies for long stretches.
- The vulnerable parts are hard to reach. The parts of the virus that don't mutate are buried under a shield of sugar molecules that antibodies can't easily target.
Traditional vaccine approaches have not worked. This new approach targets those buried, conserved regions directly.
How the new vaccine works
The team used a two-step approach:
- First, they primed the immune system with a nanoparticle that presents specific fragments of the virus — regions that don't mutate.
- Second, they boosted with a modified version of the same target, designed to trigger a more mature and broader antibody response.
In previous trials, this approach produced antibodies in only a fraction of animals. In this latest study, it worked in every single one. And the antibodies were broadly neutralising — meaning they could stop multiple HIV strains, not just one.
What "broadly neutralising" means
There are many strains of HIV, and they differ significantly from each other. A vaccine that only protects against one strain would be of limited use.
Broadly neutralising antibodies (bNAbs) are antibodies that target the conserved regions of the virus — the parts it cannot easily change without losing the ability to infect cells. A vaccine that reliably produces bNAbs is the holy grail of HIV vaccine research.
What comes next
This is still preclinical research. The next step is Phase 1 human trials, which will test the vaccine's safety and whether it produces a similar immune response in people.
Realistically:
- 2027–2028: Phase 1 human trials begin
- 2029–2031: Phase 2 trials, if Phase 1 succeeds
- 2032–2035: Phase 3 trials, if Phase 2 succeeds
- 2035+: Potential approval, if all phases succeed
This is a long road. Historically, most promising HIV vaccine candidates have failed in human trials. But this one has cleared a hurdle no previous candidate has.
What this means today
For people living with HIV today, this research does not change anything in the short or medium term. Your treatment is still your treatment. Prevention is still prevention.
What it does mean is that the scientific picture is genuinely improving. Combined with progress on long-acting prevention (lenacapavir), long-acting treatment, and cure research (venetoclax, stem cell remission cases), the field is moving in a way it has not moved in two decades.
Haven is a dating and community app built for the HIV+ community in South Africa.
Get Haven on Google Play